Quibron T: Advanced Bronchodilation for Respiratory Relief
Quibron T is a prescription medication formulated to provide comprehensive management of bronchospasm associated with chronic bronchitis, emphysema, and asthma. Its dual-action formula combines theophylline, a methylxanthine bronchodilator, with guaifenesin, an expectorant, to address both airway constriction and mucus clearance. This combination offers a targeted approach for patients requiring sustained bronchodilation and improved pulmonary function. Clinically developed for long-term maintenance therapy, Quibron T helps restore respiratory efficiency and enhance quality of life in individuals with obstructive airway diseases.
Features
- Contains theophylline anhydrous 300 mg and guaifenesin 100 mg per tablet
- Extended-release formulation for consistent 12-hour dosing
- Designed to reduce bronchospasm and improve mucus expulsion
- Available in scored tablets for accurate dosage titration
- Manufactured under strict pharmaceutical quality standards
Benefits
- Provides prolonged bronchodilation to facilitate easier breathing
- Reduces the frequency and severity of bronchospastic episodes
- Enhances mucus clearance from the respiratory tract
- Supports improved exercise tolerance and daily activity performance
- Helps maintain open airways during sleep, reducing nighttime symptoms
- Contributes to overall better management of chronic respiratory conditions
Common use
Quibron T is commonly prescribed for the management of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is also used as maintenance therapy for asthma when other bronchodilators have proven insufficient. Healthcare providers may recommend Quibron T for patients who require both bronchodilation and expectorant effects, particularly those with difficulty clearing thick respiratory secretions. The medication is typically part of a comprehensive treatment plan that may include other respiratory medications and lifestyle modifications.
Dosage and direction
Dosage must be individualized based on patient factors including age, weight, smoking status, and concomitant medications. The usual adult starting dose is one tablet every 12 hours, though some patients may require one tablet every 8 hours. Tablets should be swallowed whole and not crushed or chewed. Administration with a full glass of water is recommended. Dosage adjustments should be made gradually, with monitoring of serum theophylline levels. The optimal therapeutic range for theophylline is typically 10-20 mcg/mL. Patients should be advised to take Quibron T at consistent intervals to maintain stable blood levels.
Precautions
Patients should be monitored for signs of theophylline toxicity, particularly those with cardiac, hepatic, or renal impairment. Caution is advised in patients with seizure disorders, peptic ulcer disease, or hyperthyroidism. Smoking may increase theophylline clearance, requiring dosage adjustment. Elderly patients and those with congestive heart failure may have reduced clearance. Patients should avoid excessive consumption of xanthine-containing foods and beverages (coffee, tea, chocolate). Regular monitoring of serum theophylline levels is recommended, especially during dosage adjustments or when adding medications that may affect theophylline metabolism.
Contraindications
Quibron T is contraindicated in patients with known hypersensitivity to theophylline, guaifenesin, or any component of the formulation. It should not be used in patients with active peptic ulcer disease or seizure disorders not adequately controlled by anticonvulsant therapy. Contraindications include uncontrolled cardiac arrhythmias and hyperthyroidism. The medication is not recommended for treatment of acute bronchospasm where rapid onset is required. Use is contraindicated in patients with porphyria.
Possible side effects
Common side effects may include nausea, vomiting, headache, insomnia, and gastrointestinal discomfort. Less frequently, patients may experience nervousness, restlessness, palpitations, or tachycardia. Serious side effects requiring immediate medical attention include cardiac arrhythmias, seizures, or signs of severe allergic reaction. Guaifenesin may cause dizziness or drowsiness in some patients. The incidence and severity of side effects are often dose-related and may be minimized by proper dosage titration and monitoring of serum levels.
Drug interaction
Quibron T interacts significantly with numerous medications. CYP1A2 inhibitors (cimetidine, fluvoxamine, certain antibiotics) may increase theophylline levels. Enzyme inducers (phenytoin, carbamazepine, rifampin) may decrease levels. Concurrent use with other xanthines may increase toxicity risk. Quinolone antibiotics, macrolides, and allopurinol may elevate theophylline concentrations. The medication may potentiate the effects of sympathomimetics and may interact with beta-blockers. Patients should inform healthcare providers of all medications, including over-the-counter drugs and supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing is important for maintaining therapeutic blood levels, so patients should establish routines to minimize missed doses. If multiple doses are missed, patients should contact their healthcare provider before resuming therapy.
Overdose
Theophylline overdose can be serious and potentially fatal. Symptoms may include severe nausea/vomiting, cardiac arrhythmias, hypotension, seizures, and metabolic disturbances. Management requires immediate medical attention. Treatment may include activated charcoal if ingestion was recent, supportive care, and possibly hemoperfusion for severe cases. Serum theophylline levels should be monitored frequently. Patients and caregivers should be educated about overdose symptoms and the importance of proper dosing.
Storage
Store at room temperature (15-30°C or 59-86°F) in a dry place protected from light and moisture. Keep the container tightly closed. Do not store in bathroom areas where moisture levels may fluctuate. Keep out of reach of children and pets. Do not use if the product appears discolored or shows signs of deterioration. Properly discard any unused medication after the expiration date.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Patients should consult with a qualified healthcare provider for diagnosis and treatment recommendations. Dosage and administration should be determined by a physician familiar with the patient’s medical history and current condition. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use of this information.
Reviews
Clinical studies demonstrate Quibron T’s efficacy in improving pulmonary function tests and symptom scores in COPD patients. Many pulmonologists report satisfactory results in appropriate patient populations when serum levels are maintained within therapeutic range. Some patients report significant improvement in breathing comfort and reduced exacerbation frequency. However, the narrow therapeutic index requires careful monitoring. Individual responses vary, and some patients may experience side effects that limit tolerability. Overall, when properly dosed and monitored, Quibron T remains a valuable option in the management of chronic bronchospastic conditions.